Skip to main content
Elihu Estey, MD, Oncology, Seattle, WA, UW Medicine/University of Washington Medical Center

ElihuH.EsteyMD

Oncology Seattle, WA

Hematologic Oncology

Professor, Medicine, University of Washington School of Medicine

Dr. Estey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Estey's full profile

Already have an account?

Education & Training

  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1978 - 1979
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Neurology, 1975 - 1978
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 1973 - 1975
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1972

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2007 - 2022
  • MD State Medical License
    MD State Medical License 1983 - 1984
  • TX State Medical License
    TX State Medical License 1979 - 2010
  • NY State Medical License
    NY State Medical License 1973 - Present
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2007-2013

Publications & Presentations

PubMed

Journal Articles

  • Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...  
    Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
  • Second Cycle Remission Achievement with 7+3 and Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials  
    Brent L Wood, Roland B Walter, John E Godwin, James K Weick, Elihu H Estey, Derek L Stirewalt, Frederick R Appelbaum, Nature

Abstracts/Posters

  • Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
    Elihu H. Estey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)
    Elihu H. Estey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia
    Elihu H. Estey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • More Is Better 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
  • Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Other

Press Mentions

  • Chemotherapy for Acute Myeloid Leukemia: Where Should It Be Given?
    Chemotherapy for Acute Myeloid Leukemia: Where Should It Be Given?September 10th, 2018
  • Clinical Challenges: The Older Patient with AML
    Clinical Challenges: The Older Patient with AMLMay 24th, 2019
  • Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2018
    Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2018May 15th, 2018
  • Join now to see all

Grant Support

  • Clinical Trials In AMLNational Cancer Institute2007–2011
  • Evaluating Therapeutic Strategies In MDSNational Cancer Institute2005–2009
  • Administrative CoreNational Cancer Institute2005–2009
  • New Approaches To The Biology And Treatment Of Myelodysplastic Syndromes (MDS)National Cancer Institute2005–2007
  • Elimination Of Chemotherapy In Newly-Diagnosed APLNational Cancer Institute2003–2004
  • Core--Clinical Trials In AMLNational Cancer Institute2001–2002
  • Core--Aml DatabaseNational Cancer Institute2001–2002
  • ChemotherapyNational Cancer Institute1996–2001

Hospital Affiliations